Quick Takeaways
- Affinity Asset Advisors, LLC filed SCHEDULE 13G for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX).
- Disclosed ownership: 5.3%.
- Date of event: 23 Dec 2024.
Affinity Asset Advisors, LLC - 23 Dec 2024 SCHEDULE 13G Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Healthcare Fund, LP
- Symbol
- AVTX
- Shares outstanding
- 10,391,792 shares
- Disclosed Ownership
- 550,765 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 31 Dec 2024, 16:13:00 UTC
- Date of event
- 23 Dec 2024
- Next filing
- 13 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Affinity Asset Advisors, LLC disclosed 5.3% ownership in Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX) on 23 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Dec 2024, 16:13.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Healthcare Fund, LP | 5.3% | 550,765 | 0 | 550,765 | /s/ Michael Cho | Michael Cho | |
| Affinity Asset Advisors, LLC | 5.3% | 550,765 | 0 | 550,765 | /s/ Michael Cho | Michael Cho |